Performance Evaluation of the Real-Q Cytomegalovirus (CMV) Quantification Kit Using Two Real-Time PCR Systems for Quantifying CMV DNA in Whole Blood
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Standardized cytomegalovirus (CMV) DNA quantification is important for managing CMV disease. We evaluated the performance of the Real-Q CMV Quantification Kit (Real-Q assay; BioSewoom, Korea) using whole blood (WB), with nucleic acid extraction using MagNA Pure 96 (Roche Diagnostics, Germany). Real-time PCR was performed on two platforms: the 7500 Fast real-time PCR (7500 Fast; Applied Biosystems, USA) and CFX96 real-time PCR detection (CFX96; Bio-Rad, USA) systems. The WHO international standard, diluted with CMV-negative WB, was used to validate the analytical performance. We used 90 WB clinical samples for comparison with the artus CMV RG PCR kit (artus assay; Qiagen, Germany). Limits of detections (LODs) in 7500 Fast and CFX96 were 367 and 479 IU/mL, respectively. The assay was linear from the LOD to 106 IU/mL (R2 ≥0.9886). The conversion factors from copies to IU in 7500 Fast and CFX96 were 0.95 and 1.06, respectively. Compared with the artus assay, for values <1,000 copies/mL, 100% of the samples had a variation <0.7 log10 copies/mL; >1,000 copies/mL, 73.3% and 80.6% of samples in 7500 Fast and CFX96, respectively, had <0.5 log10 copies/mL. The Real-Q assay is useful for quantifying CMV in WB with the two real-time PCR platforms.
Abstract
Standardized cytomegalovirus (CMV) DNA quantification is important for managing CMV disease. We evaluated the performance of the Real-Q CMV Quantification Kit (Real-Q assay; BioSewoom, Korea) using whole blood (WB), with nucleic acid extraction using MagNA Pure 96 (Roche Diagnostics, Germany). Real-time PCR was performed on two platforms: the 7500 Fast real-time PCR (7500 Fast; Applied Biosystems, USA) and CFX96 real-time PCR detection (CFX96; Bio-Rad, USA) systems. The WHO international standard, diluted with CMV-negative WB, was used to validate the analytical performance. We used 90 WB clinical samples for comparison with the artus CMV RG PCR kit (artus assay; Qiagen, Germany). Limits of detections (LODs) in 7500 Fast and CFX96 were 367 and 479 IU/mL, respectively. The assay was linear from the LOD to 106 IU/mL (R2 ≥0.9886). The conversion factors from copies to IU in 7500 Fast and CFX96 were 0.95 and 1.06, respectively. Compared with the artus assay, for values <1,000 copies/mL, 100% of the samples had a variation <0.7 log10 copies/mL; >1,000 copies/mL, 73.3% and 80.6% of samples in 7500 Fast and CFX96, respectively, had <0.5 log10 copies/mL. The Real-Q assay is useful for quantifying CMV in WB with the two real-time PCR platforms.
참고문헌 (15)
- Le Page AK, "Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients", Clin Infect Dis, 56, pp.1018~1029 (2013)
- Razonable RR, "Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients", Infect Dis Clin North Am, 27, pp.317~342 (2013)
- Baldanti F, "Monitoring human cytomegalovirus infection in transplant recipients", J Clin Virol, 41, pp.237~241 (2008)
- Gerna G, "Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation", Am J Transplant, 11, pp.2463~2471 (2011)
- Kraft CS, "Interpreting quantitative cytomegalovirus DNA testing: understanding the laboratory perspective", Clin Infect Dis, 54, pp.1793~1797 (2012)
- Pang XL, "Interlaboratory comparison of cytomegalovirus viral load assays", Am J Transplant, 9, pp.258~268 (2009)
- Collaborative study to evaluate the proposed 1st WHO international standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays, "Fryer JF", World Health Organization, ~ (2010)
- CLSI, "Evaluation of detection capability for clinical laboratory measurement procedures; approved guideline-Second ed. CLSI document EP17-A2", Clinical and Laboratory Standards Institute, ~ (2012)
- Miller S, "Comparison of QIAGEN automated nucleic acid extraction methods for CMV quantitative PCR testing", Am J Clin Pathol, 133, pp.558~563 (2010)
- Lisboa LF, "The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response", Transplantation, 91, pp.231~236 (2011)
- Schnepf N, "Fully automated quantification of cytomegalovirus (CMV) in whole blood with the new sensitive Abbott RealTime CMV assay in the era of the CMV international standard", J Clin Microbiol, 51, pp.2096~2102 (2013)
- Deback C, "Use of the Roche LightCycler 480 system in a routine laboratory setting for molecular diagnosis of opportunistic viral infections: evaluation on whole blood specimens and proficiency panels", J Virol Methods, 159, pp.291~294 (2009)
- Bravo D, "Comparative evaluation of three automated systems for DNA extraction in conjunction with three commercially available real-time PCR assays for quantification of plasma Cytomegalovirus DNAemia in allogeneic stem cell transplant recipients", J Clin Microbiol, 49, pp.2899~2904 (2011)
- Edelmann A, "Performance of the MagNA Pure 96 system for cytomegalovirus nucleic acid amplification testing in clinical samples", J Clin Microbiol, 51, pp.1600~1601 (2013)
- Mengelle C, "A new highly automated extraction system for quantitative real-time PCRs from whole blood samples: routine monitoring of opportunistic infections in immunosuppressed patients", J Clin Virol, 53, pp.314~319 (2012)